Rhythm Pharmaceuticals annonce l’approbation par Santé Canada de IMCIVREE®…
<!-- Name:DistributionId Value:8834057 -->
<!-- Name:EnableQuoteCarouselOnPnr Value:False -->…
Browsing Tag
BardetBiedl
Rhythm Pharmaceuticals Announces IMCIVREE® (setmelanotide) Granted Marketing…
-- Setmelanotide now FDA-approved and EC-authorized for Bardet-Biedl syndrome (BBS) -- -- EC authorization for BBS makes Rhythm eligible to receive second $37.5M tranche under Revenue…
Rhythm Pharmaceuticals Announces FDA Approval of IMCIVREE® (setmelanotide) for Use in…
-- IMCIVREE now available for chronic weight management in adult and pediatric patients 6 years of age and older with monogenic or syndromic obesity due to Bardet-Biedl syndrome -- --…
Roundworms offer new insights into Bardet-Biedl syndrome
Scientists have identified a new role for a protein complex at the center of a human genetic disorder called Bardet-Biedl syndrome, or BBS, for which there is currently no cure.
Bardet-Biedl…
Rhythm Pharmaceuticals Announces FDA Extension of Review Period for IMCIVREE®…
-- FDA sets updated PDUFA goal date of June 16, 2022 -- -- Company also announces withdrawal of proposed Alström syndrome indication from Type II variation application under review by the…
Rhythm Pharmaceuticals Presents First-ever Data Showing Improvements in…
-- Additional oral presentation details safety and efficacy data from Phase 3 trial of setmelanotide in BBS ---- Also presenting new hunger data from SRC1 and SH2B1 cohorts in Phase 2…
Rhythm Pharmaceuticals complète la demande de variation de type II à l’Agence…
BOSTON, 15 oct. 2021 (GLOBE NEWSWIRE) -- Rhythm Pharmaceuticals, Inc. (Nasdaq : RYTM), une société biopharmaceutique au stade commercial engagée à transformer les soins des personnes…
Rhythm Pharmaceuticals schließt die Einreichung des Antrags für die Typ-II-Variation…
BOSTON, Oct. 15, 2021 (GLOBE NEWSWIRE) -- Rhythm Pharmaceuticals, Inc. (Nasdaq: RYTM), ein biopharmazeutisches Unternehmen im kommerziellen Stadium, das sich der Umgestaltung der…
Rhythm Pharmaceuticals completa la presentazione della domanda di variazione tipo II…
BOSTON, Oct. 15, 2021 (GLOBE NEWSWIRE) -- Rhythm Pharmaceuticals, Inc. (Nasdaq: RYTM), un'azienda biofarmaceutica in fase commerciale impegnata a cambiare radicalmente l'assistenza delle…
Rhythm Pharmaceuticals completa la presentación de la solicitud de variación de tipo…
BOSTON, Oct. 15, 2021 (GLOBE NEWSWIRE) -- Rhythm Pharmaceuticals, Inc. (Nasdaq: RYTM), una empresa biofarmacéutica en fase comercial comprometida con la transformación de la atención a…